CYTOKINES PROFILE (IL-4, IL-13) OF CHILDREN WITH SEVERE FORMS OF ATOPIC DERMATITIS VERSUS OTHER GRADES OF SEVERITY


  • S.M. Nedelska Zaporizhia state medical university, Ukraine
  • D.O. Vakula Zaporizhia state medical university, Ukraine
  • O.P. Pakholchuk Zaporizhia state medical university, Ukraine
Keywords: Atopic dermatitis, IL-4, IL-13, children, Th2

Abstract

CYTOKINES PROFILE (IL-4, IL-13) OF CHILDREN WITH SEVERE FORMS OF ATOPIC DERMATITIS VERSUS OTHER GRADES OF SEVERITY

References

1. Bieber, T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis// Allergy. 2019; 00:1–9.

2. Szegedi, K., Lutter, R., Res, P. C., Bos, J. D., Luiten, R. M., Kezic, S., Middelkamp-Hup, M. A. Cytokine profiles in intersti- tial fluid from chronic atopic dermatitis skin// Journal of the European Academy of Dermatology and Venereology. 2015; 29(11), 2136–2144.

3. Min-Hee Oh, Sun Young Oh, Jingning Lu, Hongfei Lou, Allen C. Myers, Zhou Zhu, Tao Zheng. TRPA1-Dependent Pruritus in IL-13–Induced Chronic Atopic Dermatitis// J Immunol 2014; 191:5371-5382.

4. Brocker, C., Thompson, D., Matsumoto, Evolutionary divergence and functions of the human interleukin (IL) gene family// Human Genomics. 2010; 5(1), 30.

5. Bao K, Reinhardt RL. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity// Cytokine. 2015; 75:25-37.

6. Tsoi LC, Rodriguez E, Degenhardt F, et al. Atopic dermatitis is an IL-13 dominant disease with greater molecular heter- ogeneity compared to psoriasis// Journal on Investigative Dermatology 2019;139(7):1480-1489.

7. Koppes SA, Brans R, Ljubojevic Hadzavdic S, Frings, Dresen MH, Rustemeyer T, Kezic S. Stratum corneum tape strip- ping: monitoring of inflammatory mediators in atopic dermatitis patients using topical therapy// International Ar- chives of Allergy Immunol. 2016;170:187-193.

8. Wong L.S., Wu T., Lee C.H. Inflammatory and Noninflammatory Itch: Implications in Pathophysiology-Directed Treat- ments// The International Journal of Molecular Sciences. 2017; 18(7).

9. Gandhi N.A., Pirozzi G., Graham N.M.H. Commonalityof the IL-4/IL-13 pathway in atopic diseases// Expert Review of Clinical Immunology. 2017; 13(5): 425–437.

10. Harris V.R., Cooper A.J. Atopic dermatitis: the new frontier// Medical Journal of Australia 2017; 207(8): 351–356.

11. Klonowska J, Glen J, Nowicki RJ, Trzeciak M. New Cytokines in the Pathogenesis of Atopic Dermatitis-New Therapeu- tic Targets. Int J Mol Sci. 2018;19(10):3086. doi:10.3390/ijms19103086

12. Stier MT, Peebles RS Jr. Innate lymphoid cells and allergic disease. Ann Allergy Asthma Immunol. 2017; 119(6): 480– 488.

13. Lee E, Lee SH, Kwon JW et al. Atopic dermatitis phenotype with early onset and high serum IL-13 is linked to the new development of bronchial hyperresponsiveness in school children// Allergy. 2016; 71(5): 692-700.

14. Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spec- trum and targeted therapies. J Allergy Clin Immunol. 2017; 139(4S): S65–S76.

15. Esaki H, Brunner PM et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin// J Allergy Clin Immunol. 2016; 138(6): 1639-1651.

16. Stier MT, Peebles RS Jr. Innate lymphoid cells and allergic disease. Ann Allergy Asthma Immunol. 2017; 119(6):480–488.

17. B. Brandt, E. Th2 Cytokines and Atopic Dermatitis. Journal of Clinical & Cellular Immunology. 2011; 02(03).

18. Metwally S.S., Mosaad Y.M., Abdel-Samee E.R. IL-13 gene expression in patients with atopic dermatitis: relation to IgE level and to disease severity// Egypt J Immunol. 2004; 11(2):171-7.

19. Oh MH, Oh SY, Lu J. TRPA1-dependent pruritus in IL-13-induced chronic atopic dermatitis// J Immunol. 2013; 1; 191(11): 5371-82.
Published
2019-12-20
How to Cite
Nedelska, S., Vakula, D., & Pakholchuk, O. (2019). CYTOKINES PROFILE (IL-4, IL-13) OF CHILDREN WITH SEVERE FORMS OF ATOPIC DERMATITIS VERSUS OTHER GRADES OF SEVERITY. Biological Markers in Fundamental and Clinical Medicine (scientific Journal), 3(2), 29-33. https://doi.org/10.29256/v.03.02.2019.escbm06